SCHEMBL1986500

SCHEMBL1986500

CCOC(=O)c1c(O)c2c(Cl)ccc(C)c2[nH]c1=O

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
ALDH1A1 P00352 1/20 0.48
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 1/20 0.47
POLB P06746 1/20 0.47
KMT2A Q03164 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
KDM5A P29375 1/20 0.47
KDM5B Q9UGL1 1/20 0.47
KDM4E B2RXH2 1/20 0.47
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
MAP3K5 Q99683 1/20 0.43
RXFP1 Q9HBX9 1/20 0.42
PTGES O14684 1/20 0.42
ALOX5 P09917 1/20 0.42
APLNR P35414 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16098758 0.87 USP2 (0.44) LMNAALDH1A1MEN1KMT2AKDM4E
SCHEMBL1983234 0.82 MEN1 (0.43) ALDH1A1MEN1KMT2AKDM4ENPC1
SCHEMBL6422773 0.82 MEN1 (0.44) LMNAALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL1033018 0.80 KDM5A (0.53) LMNAALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL16029767 0.80 MAP3K5 (0.60) MAPTSMN1; SMN2MEN1POLBKMT2A
SCHEMBL8322185 0.76 MAPT (0.49) LMNAALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL321963 0.75 KDM5A (0.54) LMNAALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL8320986 0.74 MAPT (0.46) LMNAALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL7754979 0.74 KDM5A (0.53) LMNAALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL7754982 0.73 KDM5A (0.52) LMNAALDH1A1MAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970129-A2 CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF Teva Pharmaceutical Industries Ltd. (IL) 2016-01-20 EP claimed
WO-2014153145-A2 CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2014-09-25 WO claimed
EP-2970129-A2 CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF Teva Pharmaceutical Industries Ltd. (IL) 2016-01-20 EP disclosed
WO-2014153145-A2 CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2014-09-25 WO disclosed
EP-2337779-A2 2-OXO-1,2-DIHYDRO-QUINOLINE MODULATORS OF IMMUNE FUNCTION Teva Pharmaceutical Industries Ltd. (IL) 2011-06-29 EP disclosed
WO-2010028015-A2 2-OXO-1,2-DIHYDRO-QUINOLINE MODULATORS OF IMMUNE FUNCTION AUSPEX PHARMACEUTICALS, INC (US) 2010-03-11 WO disclosed